



## NIH AIDS Reagent Program

20301 Century Boulevard  
Building 6, Suite 200  
Germantown, MD 20874  
USA

Phone: 240 686 4740  
Fax: 301 515 4015  
aidsreagent.org

### DATA SHEET

<b>Reagent:</b>	HIV-1 SF162 gp140 Trimer Recombinant Protein
<b>Catalog Number:</b>	12026
<b>Lot Number:</b>	160002
<b>Provided:</b>	100 µg of purified protein, at 1.0 mg/mL in PBS, pH 7.2. Sterile filtered. EU/mg = 0.6
<b>Molecular Weight:</b>	Runs at approximately 480 kDa on a native gel.
<b>Purity:</b>	>90% as determined by SDS-PAGE.
<b>Description:</b>	This protein consists of the SF162 envelope ectodomain. The fusion site between gp120 and gp41 has been mutated to result in a fused gp140 soluble protein. Most of the material exists in a trimeric form.
<b>Special Characteristics:</b>	Suitable for ELISA, western blot, etc. Produced in HEK-293T cells. Lectin purified.
<b>Recommended Storage:</b>	-80°C
<b>Contributor:</b>	Dr. Leo Stamatatos
<b>References:</b>	<ol style="list-style-type: none"><li>1. Cheng-Mayer C, Weiss C, Seto D, and Levy JA. Isolates of human immunodeficiency virus type 1 from the brain may constitute a special group of the AIDS virus. <i>Proc Natl Acad Sci U S A</i>. 1989 Nov;86(21):8575-9.</li><li>2. Stamatatos L1, Wiskerchen M, Cheng-Mayer C. Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication. <i>AIDS Res Hum Retroviruses</i>. 1998 Sep 1;14(13):1129-39.</li><li>3. Stamatatos L, Lim M, Cheng-Mayer C. Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates. <i>AIDS Res Hum Retroviruses</i>. 2000 Jul 1;16(10):981-94.</li></ol>

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

4. Sellhorn G, Caldwell Z, Mineart C, and Stamatatos L. Improving the expression of recombinant soluble HIV Envelope glycoproteins using pseudo-stable transient transfection. *Vaccine*. 2009 Dec 11;28(2):430-6.

**NOTE:**

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 SF162 gp140 trimer, from Dr. Leo Stamatatos." Also include the reference cited above in any publications.

**Not available for release to commercial organizations. Recipient must not use or incorporate the reagent for commercial purposes.**

**Last Updated:**

July 13, 2020

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.